ShockWave Medical, Inc.(SWAV) Stock Research - Grey Stern Research

ShockWave Medical, Inc. (SWAV) Stock Analysis

$334.75 (-0.02%)

SWAV Financial Performance


Use the table below to view ShockWave Medical, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q1 - 2024

Metric Value Ranking among Peers
Price $334.75 -
52 Week Low $157.00 -
52 Week High $334.90 -
Market Cap $12.6 Billion 6/14
Gross Margin 87% 1/14
Profit Margin 25% 1/14
EBITDA margin 19% 4/14
Q1 - 2024 Revenue $218.8 Million 8/14
Q1 - 2024 Earnings $55.3 Million 5/14
Q1 - 2024 Free Cash Flow $27.5 Million 5/14
Trailing 4 Quarters Revenue $788.0 Million 8/14
Trailing 4 Quarters Earnings $163.5 Million 6/14
Quarterly Earnings Growth 41% 5/14
Annual Earnings Growth -65% 13/14
Quarterly Revenue Growth 36% 3/14
Annual Revenue Growth 33% 2/14
Cash On Hand $281.7 Million 7/14
Short Term Debt $3.7 Million 10/14
Long Term Debt $773.1 Million 5/14

ShockWave Medical, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare ShockWave Medical, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 76.87 2/14
PS 15.95 2/14
PB 16.72 4/14
PC 44.62 4/14
Liabilities to Equity 1.19 6/14
ROA 0.10 2/14
ROE 0.22 3/14
Current Ratio 1.84 9/14
Quick Ratio 1.15 3/14
Long Term Debt to Equity 1.03 6/14
Debt to Equity 1.03 6/14
Burn Rate -11.98 13/14
Cash to Cap 0.02 10/14
CCR 0.50 8/14
EV to EBITDA 308.03 2/14
EV to Revenue 16.58 2/14

Company Details

ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.

CEO: Mr. Douglas Godshall

Website: https://www.shockwavemedical.com

Address: 5403 Betsy Ross Dr Santa Clara, CALIFORNIA

Exchange: NASDAQ Global Select

Industry: Medical Devices

ShockWave Medical, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to ShockWave Medical, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Tandem Diabetes Care, Inc. TNDM $2.6 Billion
DexCom, Inc. DXCM $25.5 Billion
Edwards Lifesciences Corporation EW $37.6 Billion
Stryker Corporation SYK $126.3 Billion
Insulet Corporation PODD $13.5 Billion
Masimo Corporation MASI $5.8 Billion
Align Technology, Inc. ALGN $16.6 Billion
Penumbra, Inc. PEN $6.9 Billion
Inspire Medical Systems, Inc. INSP $3.7 Billion
TransMedics Group, Inc. TMDX $4.6 Billion
ClearPoint Neuro, Inc. CLPT $202.6 Million
Inari Medical, Inc. NARI $3.1 Billion
Outset Medical, Inc. OM $193.4 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
SWAV Income Statements
Quarter Year Revenue Earnings
Q1 2024 $ 218.8 Million $55.3 Million
Q4 2023 $ 203.0 Million $44.3 Million
Q3 2023 $ 186.0 Million $35.0 Million
Q2 2023 $ 180.2 Million $28.9 Million
Q1 2023 $ 161.1 Million $39.1 Million
Q4 2022 $ 144.0 Million $140.9 Million
Q3 2022 $ 131.3 Million $35.0 Million
Q2 2022 $ 120.7 Million $25.6 Million

View All

SWAV Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q1 2024 $281.7 Million $1.6 Billion $776.8 Million $751.8 Million
Q4 2023 $328.4 Million $1.6 Billion $770.6 Million $668.7 Million
Q3 2023 $498.1 Million $1.5 Billion $764.9 Million $601.2 Million
Q2 2023 $141.5 Million $786.6 Million $59.1 Million $616.9 Million
Q1 2023 $280.9 Million $783.2 Million $139.6 Million $570.7 Million
Q4 2022 $156.6 Million $646.1 Million $60.4 Million $511.3 Million
Q3 2022 $127.8 Million $475.8 Million $39.8 Million $355.9 Million
Q2 2022 $99.9 Million $417.1 Million $29.8 Million $305.1 Million

View All

SWAV Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q1 2024 $27.5 Million -$8.4 Million -$46.8 Million
Q4 2023 $6.2 Million $0 -$169.7 Million
Q3 2023 $44.1 Million -$6.5 Million $357.0 Million
Q2 2023 $31.0 Million -$8.7 Million -$140.2 Million
Q1 2023 $26.8 Million -$7.2 Million $124.3 Million
Q4 2022 $41.4 Million -$11.1 Million $28.4 Million
Q3 2022 $27.3 Million -$7.2 Million $28.4 Million
Q2 2022 $23.9 Million -$6.9 Million $33.7 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions